Perspective Therapeutics FY2023 net loss $46.5M; raised $177.2M in Q1 2024 financings

Perspective Therapeutics, Inc.

Net loss $46.5M ($0.17/share) vs $10.8M ($0.08) in FY2022; R&D expenses surged to $21.3M from $0.9M.
Cash $9.2M at Dec 31, 2023; subsequent private placements & public offering raised ~$177.2M gross in Q1 2024.
Phase 1/2a trials for [212Pb]VMT-α-NET (NETs) and [212Pb]VMT01 (melanoma) advanced; Cohort 2 enrolling.
Entered collaboration with Bristol Myers Squibb for VMT01+nivolumab combo; Lantheus gets option for VMT-α-NET license.
Acquired radiopharmaceutical manufacturing facility in Somerset, NJ; sold brachytherapy business to GT Medical.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Perspective Therapeutics, Inc. reported financial results for the year ended December 31, 2023.

Period: the year ended December 31, 2023
Result: reported results

Exact text from the filing

On March 28, 2024, Perspective Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2023

View on SEC.gov

325 earnings releases filed in the last 30 days. Browse all earnings releases →

Perspective Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-24-009691

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.